Depression is one of the most common mental health conditions, but it is also one of the most treatable. For many people, psychotherapy, medication, lifestyle changes, or a combination of these approaches can significantly reduce symptoms.
For others, however, depression persists despite appropriate treatment. When someone has tried multiple treatments without achieving adequate improvement, they may be experiencing treatment-resistant depression, or TRD.
Importantly, treatment-resistant depression does not mean that depression is untreatable. It means that the treatment strategy may need to change.
What Is Treatment-Resistant Depression?
There is no single universally accepted definition of treatment-resistant depression. However, it is commonly defined as major depressive disorder that has not adequately improved after two antidepressant treatments given at an appropriate dose and for an adequate duration.
Before determining that depression is truly treatment-resistant, clinicians should also consider several important questions. Was each medication taken consistently and long enough to work? Were the doses adequate? Could another condition—such as bipolar disorder, ADHD, anxiety, PTSD, substance use, sleep apnea, thyroid disease, or another medical problem—be contributing to the symptoms?
Getting the diagnosis right is an essential part of treating difficult-to-treat depression.
How Common Are Depression and Treatment-Resistant Depression?
Depression affects millions of Americans.
According to the National Institute of Mental Health, approximately 21 million U.S. adults experienced at least one major depressive episode in 2021, representing about 8.3% of the adult population. Among adults aged 18 to 25, the rate was even higher, at 18.6%.
Unfortunately, many people do not achieve remission with their first treatment.
The landmark STAR*D study followed patients through several sequential treatment strategies. Roughly one-third achieved remission with their initial antidepressant treatment, while the likelihood of remission generally declined as additional treatments were required.
Estimates of TRD vary depending on how it is defined. One large U.S. analysis estimated that approximately 31% of adults with medication-treated major depressive disorder met criteria for treatment-resistant depression, representing about 2.8 million adults in the population studied.
That makes TRD not an unusual complication of depression, but a major public health problem.
The Unmet Need in Depression Treatment
One of the biggest challenges in depression treatment is that patients may remain on an ineffective strategy for too long.
A patient may try one medication, wait several months, switch medications, increase the dose, add another medication, and repeat the process for years. During that time, depression continues to affect work, relationships, physical health, education, parenting, and overall quality of life.
STAR*D demonstrated an important clinical reality: as the number of unsuccessful treatments increases, the probability of achieving remission with subsequent conventional medication strategies tends to decrease. Remission rates reported across sequential stages were approximately 37%, 31%, 14%, and 13%.
This does not mean additional medication trials cannot work. They certainly can. But after multiple unsuccessful treatments, it may be appropriate to reconsider the treatment strategy rather than simply repeating variations of the same approach.
The Burden of Treatment-Resistant Depression
The consequences of persistent depression extend far beyond feeling sad.
TRD is associated with greater functional impairment, decreased quality of life, increased healthcare utilization, reduced workplace productivity, and greater economic burden compared with depression that responds to treatment.
One U.S. analysis found that although patients with TRD represented about 31% of adults with medication-treated major depressive disorder, they accounted for nearly half of the estimated economic burden associated with medication-treated depression.
Persistent depression can affect virtually every area of life. Patients may withdraw socially, struggle to maintain employment or academic performance, experience problems with concentration and decision-making, lose interest in relationships or previously enjoyable activities, and develop significant disturbances in sleep, appetite, energy, and motivation.
Severe depression can also be associated with suicidal thoughts and behavior, making timely and effective treatment especially important.
Treatment Options for Treatment-Resistant Depression
There is no single treatment that is best for every patient with TRD. Treatment should be individualized based on previous medication trials, symptom severity, medical history, patient preference, side effects, and the urgency of improvement.
Medication Optimization and Augmentation
After an inadequate response to an antidepressant, options may include switching to another antidepressant or adding another medication to enhance the response.
Augmentation strategies may include medications such as certain second-generation antipsychotics, lithium, thyroid hormone, or other agents depending on the clinical situation.
STAR*D demonstrated that some patients who do not respond to an initial antidepressant can still achieve remission after switching medications or adding another treatment. However, the probability of remission generally declines after multiple unsuccessful treatment attempts.
Psychotherapy
Evidence-based psychotherapy remains an important component of depression treatment, including in patients with difficult-to-treat illness.
Approaches such as cognitive behavioral therapy can help patients identify patterns of thinking and behavior that contribute to depressive symptoms, develop coping strategies, improve functioning, and address psychosocial factors that medications alone cannot resolve.
For many patients, the most effective strategy combines biological treatments with psychotherapy rather than viewing them as alternatives.
Transcranial Magnetic Stimulation (TMS)
Transcranial magnetic stimulation, or TMS, offers an entirely different approach to treating depression.
Instead of using medication, TMS uses focused magnetic pulses to stimulate specific brain regions involved in mood regulation. Treatment is noninvasive, does not require anesthesia, and patients generally remain awake throughout treatment.
Clinical guidelines recommend considering repetitive TMS in patients who have had an inadequate response to multiple appropriate medication trials.
For patients who have experienced limited benefit from medications—or who have difficulty tolerating medication side effects—TMS provides an evidence-based treatment option using a different biological mechanism.
Esketamine (Spravato)
Another important advancement in TRD treatment is esketamine, marketed as Spravato.
Spravato is a nasal medication administered under medical supervision. Unlike traditional antidepressants, which primarily affect serotonin, norepinephrine, or dopamine systems, esketamine acts primarily through the brain’s glutamate system.
Clinical trials have demonstrated its effectiveness in treatment-resistant depression, and current clinical guidelines recognize ketamine or esketamine as an option for patients who have not responded adequately to several pharmacologic treatments.
Because of potential effects such as sedation, dissociation, and temporary increases in blood pressure, Spravato is administered in certified healthcare settings where patients can be monitored after treatment.
Electroconvulsive Therapy (ECT)
ECT remains one of the most effective treatments available for severe depression.
It may be particularly appropriate when depression is severe, accompanied by psychosis or catatonia, associated with significant suicidality, or when rapid improvement is medically necessary. It is also an important treatment option for patients who have not responded to multiple other interventions.
Although ECT has historically carried substantial stigma, modern ECT is performed under anesthesia with carefully controlled electrical stimulation and remains an essential treatment in psychiatry.
Treatment Resistance Is Not Treatment Failure
Perhaps the most important message for someone struggling with treatment-resistant depression is this:
Not responding to several treatments does not mean that you have run out of options.
Depression treatment has evolved considerably. Medication and psychotherapy remain foundational treatments, but modern psychiatry now includes additional approaches such as TMS, esketamine, and ECT that work through different biological mechanisms.
When depression has persisted despite treatment, the next step should not simply be another prescription by default. It should be a thoughtful reassessment of the diagnosis, previous treatments, medical and psychiatric contributors, and the full range of evidence-based options available.
For many patients with treatment-resistant depression, changing the treatment strategy can change the course of the illness.